NQMC Update Service: July 3, 2017 | NHS Scotland

NQMC Update Service: July 3, 2017

NHS Scotland

• Breast cancer: proportion of patients undergoing wide excision and/or an axillary sampling procedure for breast cancer as day case surgery.
• Breast cancer: proportion of patients with breast cancer (invasive or ductal carcinoma in-situ) having breast conservation surgery with final radial excision margins of less than 1 mm.
• Breast cancer: proportion of patients with breast cancer (invasive or in-situ) having breast conservation surgery who undergo re-excision or mastectomy following initial breast surgery.
• Breast cancer: proportion of patients with breast cancer having conservation surgery who receive radiotherapy to the breast.
• Breast cancer: proportion of patients with breast cancer under 30 years of age referred to a specialist clinic for genetic testing.
• Breast cancer: proportion of patients with breast cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.
• Breast cancer: proportion of patients with breast cancer who are enrolled in an interventional clinical trial or translational research.
• Breast cancer: proportion of patients with breast cancer who die within 30 days of chemotherapy treatment.
• Breast cancer: proportion of patients with breast cancer who undergo immediate breast reconstruction at the time of mastectomy.
• Breast cancer: proportion of patients with invasive breast cancer for whom the HER2 status (as detected by immunohistochemistry [IHC] and/or fluorescence in-situ hybridization [FISH] analysis) is reported within 2 weeks of core biopsy.
• Breast cancer: proportion of patients with invasive breast cancer who have a greater than or equal to 5% overall survival benefit of chemotherapy treatment predicted at 10 years that undergo adjuvant chemotherapy.
• Breast cancer: proportion of patients with invasive breast cancer who undergo assessment of the axilla by ultrasound before surgery.
• Breast cancer: proportion of patients with invasive breast cancer with suspicious morphology reported on ultrasound who undergo a fine-needle aspiration (FNA)/core biopsy of the axilla before surgery.
• Breast cancer: proportion of patients with invasive or in-situ breast cancer who have a non-operative diagnosis (core biopsy/large volume biopsy).
• Breast cancer: proportion of patients with triple negative breast cancer under 40 years of age referred to a specialist clinic for genetic testing.
• Breast cancer: proportion of surgically treated patients with breast cancer less than 20 mm whole tumour size on histology (invasive plus in-situ disease) treated by breast conservation surgery.
• Hepatopancreatobiliary (HPB) cancer: number of surgical resections for pancreatic, duodenal, or distal biliary tract cancer performed by each surgeon/centre in a given year.
• Hepatopancreatobiliary (HPB) cancer: proportion of patients undergoing resection for pancreatic cancer who receive adjuvant chemotherapy.
• Hepatopancreatobiliary (HPB) cancer: proportion of patients who undergo resection for pancreatic, duodenal, or distal biliary tract cancer.
• Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) not undergoing treatment with curative intent (liver transplantation, resection or ablative therapies) who receive trans-arterial chemoembolisation (TACE) or approved systemic anti-cancer therapy (SACT).
• Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing disease specific treatment (liver transplant, resection, ablation, trans-arterial chemoembolisation [TACE] or systemic anti-cancer therapy [SACT]) who die within 30 days of definitive treatment.
• Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing disease specific treatment with curative intent (liver transplant, resection, or ablation) who die within 90 days of definitive treatment.
• Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing either CT or MRI and with full information recorded.
• Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) who meet the current UK listing criteria for liver transplantation who are referred to the Scottish Liver Transplant Unit (SLTU).
• Hepatopancreatobiliary (HPB) cancer: proportion of patients with HPB cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.
• Hepatopancreatobiliary (HPB) cancer: proportion of patients with pancreatic, duodenal or biliary tract cancer who undergo CT of the chest, abdomen and pelvis.
• Hepatopancreatobiliary (HPB) cancer: proportion of patients with pancreatic, duodenal or distal biliary tract cancer undergoing non-surgical treatment who have a histological or cytological diagnosis.
• Hepatopancreatobiliary (HPB) cancer: proportion of patients with pancreatic, duodenal, or distal biliary tract cancer undergoing surgical resection who die within 30 and 90 days.
• Hepatopancreatobiliary (HPB) cancer: proportion of patients with pancreatic, duodenal, or distal biliary tract cancer who undergo pancreatoduodenectomy where greater than or equal to 15 lymph nodes are resected and pathologically examined.
• Prostate cancer: number of radical prostatectomy procedures performed by a surgeon over a 1 year period.
• Prostate cancer: proportion of patients presenting with metastatic prostate cancer (TanyNanyM1) treated with immediate hormone therapy and docetaxel chemotherapy.
• Prostate cancer: proportion of patients presenting with metastatic prostate cancer (TanyNanyM1) treated with immediate hormone therapy.
• Prostate cancer: proportion of patients with high risk prostate cancer undergoing radical treatment who have MRI of the prostate and isotope bone scan (or alternative whole body MRI evaluation).
• Prostate cancer: proportion of patients with intermediate risk prostate cancer undergoing radical treatment who have MRI of the prostate.
• Prostate cancer: proportion of patients with metastatic prostate cancer (TanyNanyM1) discussed at the multidisciplinary team (MDT) meeting within 4 weeks of commencing treatment.
• Prostate cancer: proportion of patients with non-metastatic prostate cancer (TanyNanyM0) discussed at the multidisciplinary team (MDT) meeting before definitive treatment.
• Prostate cancer: proportion of patients with pathologically confirmed, organ confined (stage pT2) prostate cancer who undergo radical prostatectomy in which tumour is present at the margin (i.e., positive surgical margin).
• Prostate cancer: proportion of patients with prostate adenocarcinoma who undergo prostate needle biopsy where the pathology report contains a full set of data items.
• Prostate cancer: proportion of patients with prostate cancer under active surveillance who undergo multiparametric MRI within 6 months of diagnosis.
• Prostate cancer: proportion of patients with prostate cancer under active surveillance who undergo trans-rectal ultrasound guided (TRUS) prostate re-biopsy within 14 months of diagnosis.
• Prostate cancer: proportion of patients with prostate cancer undergoing radical prostatectomy with post surgical incontinence (greater than 0 pads per day measured using a validated tool) at 1 year (10 to 14 months) post radical prostatectomy.
• Prostate cancer: proportion of patients with prostate cancer undergoing radical prostatectomy with post surgical incontinence (greater than 1 pad per day measured using a validated tool) at 1 year (10 to 14 months) post radical prostatectomy.
• Prostate cancer: proportion of patients with prostate cancer who are enrolled in an interventional clinical trial or translational research.
• Prostate cancer: proportion of patients with prostate cancer who die within 30 days of chemotherapy.
• Prostate cancer: proportion of patients with prostate cancer who undergo trans-rectal ultrasound guided (TRUS) biopsy of the prostate where a minimum of 10 cores are received by pathology.